Count GSK in for the pneumococcal vaccine race.
The British pharma is wagering $2.1 billion in cash — plus up to $1.2 billion in milestones — to buy out Affinivax and its 24-valent pneumococcal vaccine candidate, now in Phase II, as well as the technology that gave birth to the shot.
“The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said outgoing R&D chief Hal Barron, who’s leaving in August to run the cell rejuvenation startup Altos Labs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,900+ biopharma pros reading Endpoints daily — and it's free.
"celeb" - Google News
May 31, 2022 at 11:53PM
https://ift.tt/6s94PWU
MarketingRx roundup: Novartis cooks up promo with celeb chef; Pharmas launch annual ASCO social media blitz - Endpoints News
"celeb" - Google News
https://ift.tt/yJ7DYEg
Bagikan Berita Ini
0 Response to "MarketingRx roundup: Novartis cooks up promo with celeb chef; Pharmas launch annual ASCO social media blitz - Endpoints News"
Post a Comment